Nama's AI scorecard currently rates Tango Therapeutics Sell (2.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does TNGX report earnings?

Tango Therapeutics's next scheduled report is on Nov 10, 2026. Analysts expect EPS of -$0.35.

What is the TNGX price target?

The median analyst price target from 11 analysts is $46.00, with a range of $24.00 – $69.00.

Is TNGX Shariah compliant?

Nama's AAOIFI-style screen reads Tango Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Tango Therapeutics (TNGX)

Healthcare · Biotechnology · NASDAQ

Tango Therapeutics (TNGX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.63B and a free-cash-flow yield of -5.6%. Over the most recent reported fiscal year, revenue grew 48.3%. Nama's AI scorecard rates it Sell, 2.3 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.3/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +172.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-37.5%

How far the last close sits under the highest price of the past five years.

Market cap	$3.63B
Trailing P/E	—
Price / book	3.5
Price / sales	67.2
FCF yield	-5.6%
Dividend yield	—
Gross margin	-148.4%
Operating margin	-253.4%
Net margin	-229.9%
Revenue growth (YoY)	+48.3%
Revenue growth (3-yr annual)	+35.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

TNGX earnings

Next report: Nov 10, 2026 (Q3 2026, EPS estimate -$0.35). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	-$0.37	-$0.32	-15.6%	$0
Q1 2026	May 13, 2026	-$0.32	-$0.31	-3.2%	$0
Q4 2025	Mar 5, 2026	-$0.29	-$0.33	+12.1%	$0
Q3 2025	Nov 4, 2025	$0.13	-$0.07	+285.7%	$53.81M

TNGX analyst price target

Median target $46.00 from 11 analysts, ranging $24.00 – $69.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live TNGX data on Nama Insights →

TNGX FAQ

Is TNGX a buy?: Nama's AI scorecard currently rates Tango Therapeutics Sell (2.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TNGX report earnings?: Tango Therapeutics's next scheduled report is on Nov 10, 2026. Analysts expect EPS of -$0.35.
What is the TNGX price target?: The median analyst price target from 11 analysts is $46.00, with a range of $24.00 – $69.00.
Is TNGX Shariah compliant?: Nama's AAOIFI-style screen reads Tango Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.